U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799611) titled 'An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia' on Jan. 23.
Brief Summary: To evaluate the efficacy and safety of CM336 in the treatment of refractory adult primary immune thrombocytopenia
Study Start Date: Jan. 31
Study Type: INTERVENTIONAL
Condition:
Immune Thrombocytopenia (ITP)
Treatment
Intervention:
DRUG: CM336 Injection
subcutaneous CM336 administration step-up dosing Dose and frequency of CM336 according to the protocol
Recruitment Status: RECRUITING
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Disclaimer: Curated by HT Syndication....